A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation

Henrik Frithiof, Kristina Aaltonen, Lisa Rydén

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskriftPeer review

15 Citeringar (SciVal)

Sammanfattning

Amplification of the HER-2/neu (HER-2) proto-oncogene occurs in 10%–15% of primary breast cancer, leading to an activated HER-2 receptor, augmenting growth of cancer cells. Tumor classification is determined in primary tumor tissue and metastatic biopsies. However, malignant cells tend to alter their phenotype during disease progression. Circulating tumor cell (CTC) analysis may serve as an alternative to repeated biopsies. The Food and Drug Administration-approved CellSearch system allows determination of the HER-2 protein, but not of the HER-2 gene. The aim of this study was to optimize a fluorescence in situ hybridization (FISH)-based method to quantitatively determine HER-2 amplification in breast cancer CTCs following CellSearch-based isolation and verify the method in patient samples.
Originalspråkengelska
Sidor (från-till)7095-7103
TidskriftOncoTargets and Therapy
Volym2016
Utgåva9
DOI
StatusPublished - 2016

Ämnesklassifikation (UKÄ)

  • Cancer och onkologi

Fingeravtryck

Utforska forskningsämnen för ”A FISH-based method for assessment of HER-2 amplification status in breast cancer circulating tumor cells following CellSearch isolation”. Tillsammans bildar de ett unikt fingeravtryck.

Citera det här